// App-Quantinova.ai

: Efficacy of Ibrutinib-Rituximab versus Real-World (RW) Treatments for Patients with Waldenström's Macroglobulinemia (WM): Adjusted Comparison of iNNOVATE and the Lyon-Sud RW Database

Researchers

Presenter

  • Lionel Karlin

Principal Investigators

  • Herv Besson

  • Christoph Tapprich

  • Jamie Garside

  • Gilles Salles

Medical Centers

  • Laboratory of hematology, Centre Hospitalier Lyon-Sud, Hospices Civils de Lyon, Universite Claude Bernard, Pierre Benite, France

  • Janssen EU HEMAR Statistics & Modelling,Beerse,Belgium

  • Janssen-Cilag GmbH, Neuss, Germany

  • Janssen EMEA HEMAR, High Wycombe, United Kingdom

Locations

  • France

  • Belgium

  • Germany

  • United Kingdom

Companies

  • JB Medical Ltd.

Study Components

Therapeutic Area

  • N/A

Disease

  • N/A

Biomarkers

  • N/A

Drug/Treatment

  • Ibrutinib

  • Rituximab

Outcome

  • N/A

Study Design

  • Cohort

Phase

  • III

Study Id's

  • NCT01614821

  • NCT02165397

Sponsors

  • Janssen Pharmaceutical

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved